Back

Engineered flavonoid disrupts mitochondrial AIF/CHCHD4 complex for targeted cancer therapy

LAI, H.-T.; Dias-Pedroso, D.; Marques Da Costa, M. E.; Fernandes, R.; Nguyen, T. N. A.; Bawa, O.; Khneisser, P.; Dokudovskaya, S.; Kroemer, G.; Marchais, A.; Gaspar, N.; Geoerger, B.; Diane, O.; Mazzanti, L.; Ha Duong, T.; Lewin, G.; Ferrie, L.; Figadere, B.; Brenner, C.

2025-03-15 pharmacology and toxicology
10.1101/2025.03.13.642976 bioRxiv
Show abstract

Oncogenic metabolism depends on multifaceted mechanisms, including bidirectional inter-organelle communication between mitochondria and the nucleus, facilitating cellular adaptation at the transcriptomic, proteomic, and metabolomic levels. The mitochondrial protein complex composed of apoptosis-inducing factor (AIF) and coiled-coil-helix-coiled-coil-helix domain-containing protein 4 (CHCHD4) is essential for this mitochondrio-nuclear communication. The AIF/CHCHD4 complex mediates the mitochondrial import of cysteine-enriched nuclear gene-encoded proteins, thereby adapting the mitochondrial proteome to cellular energy demands. We report the discovery of M30-E05, an engineered flavonoid that binds to the NADH pocket of AIF, preventing its dimerization and disrupting the AIF/CHCHD4 complex. Molecular docking and gel electrophoresis analysis of mitochondrial AIF/CHCHD4 substrates expression confirm this mechanism. In cancer cells, M30-E05 reduces the expression of nuclear gene-encoded mitochondrial proteins such as AIF, CHCHD4, COX17, and MICU1. In addition, M30-E05 fragments the mitochondrial network and impairs mitochondrial respiration, causing profound alterations, particularly in lipid and aminoacid metabolism, as revealed by kinetic measurements of oxygen consumption and mass spectrometric metabolomics. Importantly, M30-E05 significantly reduces the viability of a human adult and pediatric osteosarcoma cancer cell panel, including those from patient-derived xenografts (PDX) of osteosarcomas, and induces apoptosis. When orally administered for two weeks to immunodeficient NSG mice, M30-E05 inhibited tumor growth in a subcutaneous PDX xenograft model without apparent toxicity. We anticipate that M30-E05, as a first-in-class metabolic inhibitor, could serve as the lead compound for a new class of targeted antineoplastic agents. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=120 SRC="FIGDIR/small/642976v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@1b1add9org.highwire.dtl.DTLVardef@cac7corg.highwire.dtl.DTLVardef@101c9corg.highwire.dtl.DTLVardef@1c6845f_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
ACS Central Science
66 papers in training set
Top 0.1%
14.2%
2
Cell Chemical Biology
81 papers in training set
Top 0.1%
10.3%
3
Nature
575 papers in training set
Top 3%
8.3%
4
Nature Communications
4913 papers in training set
Top 33%
4.8%
5
Nucleic Acids Research
1128 papers in training set
Top 6%
3.6%
6
Journal of Medicinal Chemistry
68 papers in training set
Top 0.3%
3.6%
7
Science
429 papers in training set
Top 9%
3.6%
8
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 20%
3.6%
50% of probability mass above
9
Angewandte Chemie International Edition
81 papers in training set
Top 1%
3.2%
10
eLife
5422 papers in training set
Top 32%
2.6%
11
Journal of the American Chemical Society
199 papers in training set
Top 2%
2.4%
12
ACS Chemical Biology
150 papers in training set
Top 0.8%
2.1%
13
Nature Chemical Biology
104 papers in training set
Top 1%
2.1%
14
Chemical Science
71 papers in training set
Top 0.8%
1.9%
15
Science Advances
1098 papers in training set
Top 16%
1.8%
16
Cancer Letters
32 papers in training set
Top 0.2%
1.8%
17
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.5%
18
Experimental & Molecular Medicine
14 papers in training set
Top 0.1%
1.5%
19
Molecular Therapy
71 papers in training set
Top 2%
1.3%
20
Clinical and Translational Medicine
30 papers in training set
Top 0.5%
1.2%
21
Molecular Cancer Therapeutics
33 papers in training set
Top 0.5%
1.2%
22
Science Translational Medicine
111 papers in training set
Top 5%
0.8%
23
Cell
370 papers in training set
Top 17%
0.7%
24
PLOS ONE
4510 papers in training set
Top 68%
0.7%
25
Acta Pharmaceutica Sinica B
11 papers in training set
Top 1.0%
0.7%
26
Cancers
200 papers in training set
Top 5%
0.7%
27
Cancer Research
116 papers in training set
Top 4%
0.6%
28
Pharmacology Research & Perspectives
11 papers in training set
Top 0.4%
0.6%
29
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.6%
30
npj Aging
15 papers in training set
Top 1%
0.6%